The downregulation of CD163 and CCR1 may reflect key pathological changes in the development and progression of NAFLD and HF, suggesting their potential as diagnostic and therapeutic targets. The gene discussed is CCR1; the disease is metabolic dysfunction-associated steatotic liver disease.